LY2127399

DRUG16 trials

Sponsors

Eli Lilly and Company, Applied Molecular Evolution

Conditions

Arthritis, RheumatoidAutoimmune DiseaseConnective Tissue DiseaseKidney Failure, ChronicMultiple MyelomaRelapsing-Remitting Multiple SclerosisRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

CompletedNCT00689507

Applied Molecular EvolutionMultiple Myeloma

Start: 2008-03-31End: 2014-05-31Updated: 2015-06-29

A Study of Japanese Rheumatoid Arthritis Participants

CompletedNCT01253291

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2010-05-31End: 2014-03-31Updated: 2019-03-01

Phase 2

A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis

CompletedNCT00308282

Eli Lilly and CompanyArthritis, Rheumatoid

Start: 2006-03-28End: 2007-10-18Updated: 2019-09-10

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

CompletedNCT00689728

Eli Lilly and CompanyArthritis, Rheumatoid

Start: 2008-06-30End: 2010-05-31Updated: 2018-12-06

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

CompletedNCT00785928

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2008-10-31End: 2010-12-31Updated: 2018-07-10

An Open Label Extension Study in Participants With Rheumatoid Arthritis

CompletedNCT00837811

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2009-02-28End: 2012-01-31Updated: 2018-04-25

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

CompletedNCT00882999

Eli Lilly and CompanyRelapsing-Remitting Multiple Sclerosis

Start: 2009-04-30End: 2012-06-30Updated: 2018-11-15

A Study in Participants With End-Stage Renal Disease

CompletedNCT01200290

Eli Lilly and CompanyKidney Failure, Chronic

Start: 2011-04-30End: 2014-03-31Updated: 2018-05-14

A Study of LY2127399 in Rheumatoid Arthritis

TerminatedNCT01576549

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2012-05-31End: 2013-05-31Updated: 2018-04-26

Phase 3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

CompletedNCT01196091

Eli Lilly and CompanyAutoimmune Disease, Connective Tissue Disease, Systemic Lupus Erythematosus

Start: 2010-12-31End: 2015-06-30Updated: 2018-06-12

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

TerminatedNCT01198002

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2010-12-31End: 2014-01-31Updated: 2018-05-08

A Rheumatoid Arthritis Study in Participants

CompletedNCT01202760

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2011-01-31End: 2013-07-31Updated: 2018-04-25

A Study in Participants With Rheumatoid Arthritis

TerminatedNCT01202773

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2011-01-31End: 2014-01-31Updated: 2018-05-14

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

CompletedNCT01205438

Eli Lilly and CompanyAutoimmune Disease, Connective Tissue Disease, Systemic Lupus Erythematosus

Start: 2011-01-31End: 2015-03-31Updated: 2018-07-17

An Open Label Study for Participants With Rheumatoid Arthritis

TerminatedNCT01215942

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2011-06-30End: 2014-02-28Updated: 2018-06-11

On Open-Label Study in Participants With Systemic Lupus Erythematosus

TerminatedNCT01488708

Eli Lilly and CompanyAutoimmune Disease, Connective Tissue Disease, Systemic Lupus Erythematosus

Start: 2012-01-31End: 2015-10-31Updated: 2018-05-17

Related Papers

XIST EXPRESSION IN MALES WITH SYSTEMIC LUPUS ERYTHEMATOSUS: BIMODAL DISTRIBUTION AND PARTIAL X-CHROMOSOME INACTIVATION

The Journal of Rheumatology2025-05-20

Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study (P3.397)

Neurology2018-04-1011 citations

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

2018-01-0110 citations

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials

Lupus2016-05-2529 citations

Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation.

2016-01-1821 citations

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

2015-09-03171 citations

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

2015-08-20163 citations

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open2015-08-0119 citations

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.

2015-04-1428 citations

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.

2014-08-2912 citations

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.

2013-04-1841 citations

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.

2012-12-2553 citations